The FDA granted priority-review designation for Sanofi and Regeneron's colorectal cancer drug Zaltrap, or aflibercept. The partners said the drug failed to meet the main endpoint of extending overall survival in patients with metastatic androgen-independent prostate cancer in a late-stage trial.
FDA expedites review of Sanofi-Regeneron colon cancer drug
SmartBrief Job Listings for Health Care
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|